candesartan cilexetil has been researched along with o-(chloroacetylcarbamoyl)fumagillol in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Akagi, T; Egami, K; Ikeda, H; Imaizumi, T; Ishii, M; Matsuishi, T; Murohara, T; Sasaki, K; Shimada, T; Shintani, S; Sugaya, T | 1 |
2 other study(ies) available for candesartan cilexetil and o-(chloroacetylcarbamoyl)fumagillol
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Cyclohexanes; Endothelial Growth Factors; Intercellular Signaling Peptides and Proteins; Lymphokines; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Sesquiterpenes; Tetrazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |